MARIALUIGIA FANTACUZZI

Prof. MARIALUIGIA FANTACUZZI

Department of Pharmacy, “G.d’Annunzio” University of Chieti-Pescara, Italy
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2017 in ChemMedChem
Verified
Journal Article
Open access
PDF file
Barbara De FilippisBarbara De Filippis
Barbara De Filippis
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
Letizia GiampietroLetizia Giampietro
Letizia Giampietro
Cristina MaccalliniCristina Maccallini
Cristina Maccallini
Rosa AmorosoRosa Amoroso
Rosa Amoroso
Stilbene is an abundant structural scaffold in nature, and stilbene‐based compounds have been widely reported for their biological activity. Notably, (E)‐resveratrol and its natural stilbene‐containing derivatives have been extensively investigated as cardioprotective, potent antioxidant, anti‐inflammatory, and anticancer agents. Starting from its potent chemotherapeutic activity against a wide variety of cancers, the stilbene scaffold has been subject to synthetic manipulations with the aim of obtaining new analogues with improved anticancer activity and better bioavailability. Within the last decade, the majority of new synthetic stilbene derivatives have demonstrated significant anticancer activity against a large number of cancer cell lines, depending on the type and position of substituents on the stilbene skeleton. This review focuses on the structure–activity relationship of the key compounds containing a stilbene scaffold and describes how the structural modifications affect their anticancer activity.

1 January 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
BFBarbara De Filippis
Barbara De Filippis
Marialucia GalloriniMarialucia Gallorini
Marialucia Gallorini
AAAlessandra Ammazzalorso
Alessandra Ammazzalorso
Letizia GiampietroLetizia Giampietro
Letizia Giampietro
Rosa AmorosoRosa Amoroso
Rosa Amoroso

1 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
Marialucia GalloriniMarialucia Gallorini
Marialucia Gallorini
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
NGNicola Gambacorta
Nicola Gambacorta
BFBarbara De Filippis
Barbara De Filippis
Rosa AmorosoRosa Amoroso
Rosa Amoroso

26 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Cristina MaccalliniCristina Maccallini
Cristina Maccallini
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
Barbara De FilippisBarbara De Filippis
Barbara De Filippis
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
Letizia GiampietroLetizia Giampietro
Letizia Giampietro
Rosa AmorosoRosa Amoroso
Rosa Amoroso
Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. Since epigenetic changes are highly implicated in TNBC tumorigenesis and development, inhibitors of histone deacetylases (HDACIs) could represent a promising therapeutic strategy. Although clinical trials involving single HDACIs showed disappointing results against TNBC, recent studies emphasize the high potential impact of HDACIs in controlling TNBC. In addition, encouraging results stem from new compounds designed to obtain isoform selectivity and/or polypharmacological HDAC approach. The present review provides a discussion of the HDACIs pharmacophoric models and of the structural modifications, leading to compounds with a potent activity against TNBC progression.

9 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
Barbara De FilippisBarbara De Filippis
Barbara De Filippis
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the breast cancer treatment that, in combination with the endocrine therapy, dramatically improved the survival outcomes both in first and later line settings. The developments of the last five years in the search for new selective CDK4/6 inhibitors with increased selectivity, treatment efficacy, and reduced adverse effects are reviewed, considering the small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) approaches, mainly pointing at structure-activity relationships, selectivity against different kinases and antiproliferative activity.

1 August 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
AGAntonella Giancristofaro
Antonella Giancristofaro
ADAlessandra D’aNgelo
Alessandra D’aNgelo
BFBarbara De Filippis
Barbara De Filippis
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
RARosa Amoroso
Rosa Amoroso